Skip to main content

Table 2 Median and first and third quartile levels (pg/ml) and medianfold-increase in plasma NT-pro-BNP in patients receiving sunitinib according to clinical outcome after the first two cycles of treatment.

From: Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma

 

Baseline

Actual values after baseline

Median fold

change to baseline

    

Day15

Day30

Day45

Day75

    

Clinical outcome

N

Median

Q1-Q3

Median

Q1-Q3

Median

Q1-Q3

Median

Q1-Q3

Median

Q1-Q3

Day15

Day30

Day45

Day75

Disease progression

9

61.1

39.5-120.4

132.3

75.7-341.2

145.8

96.6-553.3

576.8

54.5-827.0

344.0

191.9-1071.0

2.8

3.9

8.9

5.4

Clinical benefit

27

149.0

97.7-535.6

179.5

80.5-337.5

215.2

87.4-380.6

241.7

111.2-555.5

260.1

120.6-637.4

1.0

1.0

0.9

0.9

p-value

0.021

0.768

0.951

0.726

0.374

0.0002

0.002

0.003

0.025

  1. Note: Q1 and Q3 are the first and third quartiles respectively